In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1841-1845

  Fink, Daniel ^a,b   Zheng, Hua ^a,b   Nebel, Sibylle ^a,b   Norris, Paula S ^b   Aebi, Stefan ^a,b   Lin, Tzu Ping ^a,b   Nehmé, Alissar ^a,b   Christen, Randolph D ^a,b   Haas, Martin ^b   MacLeod, Carol L ^a,b   Howell, Stephen B ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OXALIPLATIN;

ANIMAL MODEL; ARTICLE; BASE MISPAIRING; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA REPAIR; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; COLORECTAL NEOPLASMS; DNA REPAIR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 15444350120     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kavanagh, J., Tresukosol, D., Edwards, C., Freedman, R., Gonzalez de Leon, C., Fishman, A., Mante, R., Hord, M., and Kudelka, A. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol., 13: 1584-1588, 1995.
2. Fishel, R., and Kolodner, R. D. Identification of mismatch repair genes and their role in the development of cancer. Curr. Opin. Genet. Dev., 5: 382-395, 1995.
3. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
4. Bhattacharyya, N. P., Skandalis, A., Ganesh, A., Groden, J., and Meuth, M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 91: 6319-6323, 1994.
5. Hess, P., Aquilina, G., Dogliotti, E., and Bignumi, M. Spontaneous mutations at aprt locus in a mammalian cell line defective in mismatch recognition. Somat. Cell Mol. Genet., 20: 409-421, 1994.
6. Baker, S. M., Plug, A. W., Prolla, T. A., Bronner, C. E., Harris, A. C., Yao, X., Christie, D-M., Monell, C., Arnheim, N., Bradley, A., Ashley, T., and Liskay, M. Involvement of mouse MLH1 in DNA mismatch repair and meiotic crossing over. Nat. Genet., 13: 336-342, 1996.
7. Andrews, P. A., Jones, J. A., Varki, N. M., and Howell, S. B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun., 2: 93-100, 1990.
8. Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and Boland, C. R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res., 54: 4308-4312, 1994.
9. de Wind, N., Dekker, M., Berns, A., Radman, M., and te Riele, H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell, 82: 321-330, 1995.
10. Crameri, A., Whitehorn, E. A., Tate E., and Stemmer, W. P. C. Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat. Biotechnol., 14: 315-319, 1996.
11. Naviaux, R. K., Costanzi, E., Haas, M., and Verma, I. M. The pCL vector system: Rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol., 70: 5701-5705, 1996.
12. Mathé, G., Kidani, Y., Noji, M., Maral, R., Bourut, G., and Chenu, E. Antitumor activity of l-OHP in mice. Cancer Lett., 27: 135-143, 1985.
13. Geran, R. I., Greenberg, N. H., Macdonald, M. M., Schumacher, A. M., and Abbott, B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 3: 1-88, 1972.
14. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R., Boland, C. R., Koi, M., Fishel, R., and Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56: 3087-3090, 1996.
15. Boyer, J. C., Umar, A., Risinger, J. I., Lipford, J. R., Kane, M., Yin, S., Barrett, J. C., Kolodner, R. D., and Kunkel, T. A. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res., 55: 6063-6070, 1995.
16. Kat, A., Thilly, W. G., Fang, W. H., Longley, M. J., Li, G-M., and Modrich, P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. USA, 90: 6424-6428, 1993.
17. 2 cell cycle checkpoint. Cancer Res., 55: 3721-3725, 1995.
18. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA, 93: 6443-6447, 1996.
19. Palombo, F., Gallinari, P., Iaccarino, I., Lettieri, T., Hughes, M., D'Arrigo, A., Truong, O., Hsuan, J. J., and Jiricny, J. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science (Washington DC), 268: 1912-1914, 1995.
20. Drummond, J. T., Li, G-M., Longley, M. J., and Modrich, P. Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science (Washington DC), 268: 1909-1912, 1995.
21. Risinger, J. I., Umar, A., Boyd, J., Berchuck, A., Kunkel, T. A., and Barrett, J. C. Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. Nat. Genet., 14: 102-105, 1996.
22. Li, G-M., and Modrich, P. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc. Natl. Acad. Sci. USA, 92: 1950-1954, 1995.
23. Skipper, H. E., Schabel, F. M., and Lloyd, H. H. Experimental therapeutics and kinetics: Selection and overgrowth of specifically and permanently drug-resistant tumor cells. Semin. Hematol., 15: 207-219, 1978.
24. Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R. M., and Brown, R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res., 56: 1374-1381, 1996.
25. Markowitz, S., Wang, J., Myeroff, L., Parsons, R. E., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., Brattain, M., and Willson, J. K. V. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science (Washington DC), 268: 1336-1338, 1995.
26. Kinzler, K. W., and Vogelstein, B. Lessons from hereditary colorectal cancer. Cell, 87: 159-170, 1996.